Stock-based Compensation (Tables)

12 Months Ended

Dec. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

Stock-based compensation expense recognized in each category of the consolidated statement of operations for the years ended December 31, 2019, 2018 and 2017 was as follows (in thousands):

	Year Ended December 31,
	2019		2018		2017
Veterinary invoice expense	$	697	$	571	$	355
Other cost of revenue	353		356		239
Technology and development	364		209		216
General and administrative	3,312		2,304		1,887
Sales and marketing	2,120		1,335		722
Total expensed stock-based compensation	6,846		4,775		3,419
Capitalized stock-based compensation	204		175		143
Total stock-based compensation	$	7,050	$	4,950	$	3,562

As of December 31, 2019, the Company had 206,387 unvested stock options and 581,943 unvested restricted stock awards and restricted stock units. Total stock-based compensation expense of $1.4 million related to unvested stock options and $14.6 million related to unvested restricted stock awards and restricted stock units is expected to be recognized over a weighted-average period of approximately 1.1 years and 3.0 years, respectively.

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

The weighted-average grant date fair value per share and the fair value of options vested were as follows for the years ended December 31, 2019, 2018, and 2017:

	Weighted Average Grant Date Fair Value per Share		Fair Value of Options Vested (in thousands)
Year:
2017	$	7.25	$	6,313
2018	$	—	$	2,665
2019	$	—	$	1,591

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

Stock Options

The grant date fair value of stock option awards are estimated on the date of grant using the Black-Scholes option-pricing model. The Company did not grant any stock options during the years ended December 31, 2019 and 2018. For the year ended December 31, 2017, valuation assumptions are presented in the following table:

	Year Ended December 31,
	2017
Valuation assumptions:
Expected term (in years)	6.25
Expected volatility	37.1%-39.8%
Risk-free interest rate	1.8%-2.2%
Expected dividend yield	—%

Schedule of Share-based Compensation, Stock Options, Activity

	Number of Options		Weighted Average Exercise Price per Share		Aggregate Intrinsic Value (in thousands)
Outstanding as of January 1, 2017	4,123,023		$	5.06	$	43,185
Granted	657,339		17.74		—
Exercised	(670,823	)	3.80		10,392
Forfeited	(103,140	)	12.25		—
Outstanding as of December 31, 2017	4,006,399		7.16		88,578
Granted	—		—		—
Exercised	(1,292,037	)	2.82		36,625
Forfeited	(92,859	)	15.36		—
Outstanding as of December 31, 2018	2,621,503		9.01		43,136
Granted	—		—		—
Exercised	(510,268	)	5.28		13,151
Forfeited	(13,257	)	18.23		—
Outstanding as of December 31, 2019	2,097,978		9.86		57,907
Exercisable at December 31, 2019	1,891,591		$	9.04	$	53,760

As of December 31, 2019, stock options outstanding and stock options exercisable had a weighted average remaining contractual life of 5.1 years and 4.8 years, respectively.

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

The below table summarizes the Company’s restricted stock award and restricted stock unit activity for the years ended December 31, 2019, 2018 and 2017:

	Number of  Shares		Weighted Average Grant Date Fair Value per Share
Unvested shares as of January 1, 2017	350,631		$	4.77
Granted	23,659		30.19
Vested	(116,877	)	4.77
Forfeited	(571	)	30.19
Unvested shares as of December 31, 2017	256,842		4.77
Granted	375,313		28.10
Vested	(149,213	)	9.74
Forfeited	(31,782	)	28.57
Unvested shares as of December 31, 2018	451,160		22.16
Granted	459,523		30.03
Vested	(276,184	)	18.20
Forfeited	(52,556	)	29.85
Unvested shares as of December 31, 2019	581,943		$	29.56